# Abnormal Uterine Bleeding, Fibroids and Polyps for NEET PG OBG: PALM-COEIN, ICMR HMB Pathway, Endometrial Sampling, FIGO Fibroid Types and Hysterectomy Rules

Source: https://tracknation.in/story/abnormal-uterine-bleeding-fibroids-and-polyps-for-neet-pg-obg-palm-coein-icmr-hmb-pathway-endometrial-sampling-figo-fibroid-types-and-hysterectomy-rules (TrackNation — free UPSC notes with PYQs)

> NEET PG Gynaecology: normal menstrual parameters, PALM-COEIN, ICMR 2025 heavy menstrual bleeding workflow (tests, ET >12 mm sampling, hyperplasia, acute bleed with IV tranexamic acid, progestogen regimens, LNG-IUS), fibroid FIGO types, symptoms, degenerations and treatment, adenomyosis, and ICMR hysterectomy dos and don'ts, with a diagram, hooks, MCQs and cards.

## Start Here

🎯 **Exam priority: Very high.** *Expect: normal cycle limits, PALM-COEIN, when to sample the endometrium, first-line medical
treatment, acute heavy bleeding, hyperplasia with/without atypia, FIGO fibroid types, red degeneration, adenomyosis vs fibroid, and the ICMR
rules on when not to do a hysterectomy.*

CBME mapping: **OG24** (AUB) and **OG29** (fibroids). Indian anchors: ICMR Standard Treatment Workflows (December 2025)
for heavy menstrual bleeding, uterine fibroids and polyps, and hysterectomy for benign conditions.

*PALM-COEIN, the ICMR heavy-bleeding pathway, fibroid types and hysterectomy rules. Drawn by TrackNation.*

## Definitions and Work-up (MSD, ICMR)

- Normal cycle (MSD): every **24–38 days**, bleeding **≤8 days**, volume **<80 ml**. More than 80 ml = heavy
menstrual bleeding (ICMR uses the **pictorial blood assessment chart**).

- **PALM-COEIN**: structural — **P**olyp, **A**denomyosis, **L**eiomyoma, **M**alignancy/hyperplasia;
non-structural — **C**oagulopathy, **O**vulatory dysfunction, **E**ndometrial, **I**atrogenic, **N**ot yet
classified. **Ovulatory dysfunction** is the commonest cause, mostly in **adolescents and women >45**. Regular heavy periods suggest
a structural cause.

- **Exclude pregnancy** in every woman of reproductive age. Tests: Hb, CBC with smear, BT/CT (and von Willebrand tests where
indicated), LFT, TSH, USG. Luteal progesterone ≥3 ng/ml confirms ovulation.

- **Endometrial sampling** (ICMR): women **>40** with **endometrial thickness >12 mm** or **high risk**
(low parity, obesity, PCOD, diabetes). Postmenopausal bleeding is referred to a higher centre.

## Treating Heavy Menstrual Bleeding (ICMR 2025)

- **Conservative treatment first**, especially in younger women. Options: **tranexamic acid** during bleeding (+ mefenamic
acid if painful), **NSAIDs**, **combined pills** if contraception is wanted, **progestogens**, **LNG-IUS**,
**ormeloxifene**; ablation if these fail.

- **Norethisterone gives the best haemostasis** among progestogens. Regimen: norethisterone or MPA (max **40 mg/day**) from day 5
for **3 weeks**, for **4–6 cycles**; LNG-IUS is the alternative.

- **Acute heavy bleed**: **IV tranexamic acid 1 g** slowly, then **0.5–1 g orally 6–8-hourly for 5 days**;
**transfuse if Hb <7 g/dL**; Hb <7 or ongoing loss at a lower level → refer.

- **Hyperplasia without atypia**: **LNG-IUS** or progestogens for 6 months (hysterectomy if medical treatment fails).
**Atypical hyperplasia**/malignancy → refer; hysterectomy.

## Fibroids, Polyps and Adenomyosis (ICMR, MSD)

- **Fibroids** (leiomyomas): the **commonest pelvic/benign uterine tumour**, ~**80% of women** in a lifetime (ICMR);
monoclonal, **oestrogen-dependent** — grow in reproductive years, shrink after menopause. Risk ↑ early menarche, obesity, hypertension; ↓
with parity ≥3. **Sarcoma <1%**.

- **FIGO types**: **0** pedunculated intracavitary, **1** <50% intramural, **2** >50% intramural (0–2
submucous); **3–4** intramural; **5–7** subserous (7 pedunculated); **8** cervical/parasitic.

- Symptoms: **heavy bleeding**, pressure/urinary symptoms, mass, pain, infertility. Red flags: severe anaemia, pain of
**degeneration** or torsion, **acute urinary retention**. Degenerations: hyaline, cystic, calcific, fatty, **red (pregnancy)**.

- Treatment: **asymptomatic fibroids <5 cm need no treatment**. Medical — tranexamic acid, LNG-IUS (normal cavity), progestogens;
GnRH analogues short-term only (rebound). **Polyps and suitable submucous fibroids → hysteroscopic removal**. **Myomectomy** for younger
or low-parity women; **UAE**; hysterectomy avoided under 35 where possible.

- **Adenomyosis**: endometrium inside the myometrium → heavy, painful periods and a **diffusely (globularly) enlarged uterus**,
usually not beyond **12 weeks** size; TVS or MRI.

## When to Do — and Not Do — a Hysterectomy (ICMR 2025)

- Only when childbearing is complete; in women **under 40 or of low parity a second gynaecologist's opinion is mandatory**.

- Indications: symptomatic fibroids failing medical treatment, **asymptomatic fibroid uterus ≥14 weeks**, fibroids causing
**hydroureteronephrosis**, rapid growth or severe anaemia; HMB failing medical treatment; endometriosis failing treatment;
**third/fourth-degree prolapse**; **atypical hyperplasia**; **CIN II with poor compliance or CIN III**; recurrent postmenopausal
bleeding.

- **Not for**: white discharge, cervicitis, minor prolapse, small (<5 cm) asymptomatic fibroids (<12-week uterus), simple ovarian
cysts ≤5 cm, non-specific pain.

- **Preserve ovaries** in most premenopausal women; add **bilateral salpingectomy** to cut later ovarian cancer risk. After surgery:
no heavy lifting and abstinence for **8 weeks**.

## Traps the Examiner Sets

- Rule out pregnancy first, even in teenagers.

- Endometrial thickness >12 mm in a woman over 40 → sample, don't just treat.

- Asymptomatic fibroid under 5 cm → no treatment.

- Hysterectomy in a young woman needs a second opinion; ovaries are kept.

## Memory Hooks & Shortcuts

*Shortcuts to lock in this article's numbers and lists. Each one only re-packages facts proven above.*

- 🧠 **PALM is solid (you can see it), COEIN is not** — PALM-COEIN

- 🧠 **ICMR sampling rule '40-12': over 40 and ET over 12 mm → sample** — sampling

- 🧠 **Fibroid FIGO: '0-1-2 inside, 3-4 in the wall, 5-6-7 outside, 8 elsewhere'** — FIGO

- 🧠 **'Red in pregnancy' — red degeneration** — degeneration

- 🧠 **Hysterectomy under 40: 'two gynaecologists, two ovaries kept, two tubes out'** — hysterectomy

## Rapid-Revision Cards

- 24–38 d; ≤8 d; <80 ml.

- Polyp, Adenomyosis, Leiomyoma, Malignancy.

- Coagulopathy, Ovulatory, Endometrial, Iatrogenic, NYC.

- Ovulatory dysfunction.

- Exclude pregnancy.

- Test for vWD.

- >40 + ET >12 mm or high risk.

- Obese, PCOD, diabetic, low parity.

- Norethisterone.

- 3 wk × 4–6 cycles; ≤40 mg/d.

- IV TXA 1 g; transfuse if Hb <7.

- LNG-IUS / progestogen 6 mo.

- Hysterectomy.

- ~80%.

- Submucous.

- Pedunculated subserous / cervical.

- No treatment.

- Pregnancy.

- Globular uterus ≤12 wk.

- Second opinion.

- Keep ovaries; remove tubes.

## Sources

*Facts in this article were checked against these documents.*

- Standard Treatment Workflows: Heavy Menstrual Bleeding; Uterine Fibroids and Polyps; Hysterectomy for Benign Gynaecological Conditions — Indian Council of Medical Research / DHR, 2025

- MSD Manual Professional: Abnormal Uterine Bleeding; Uterine Fibroids; Uterine Adenomyosis — Merck & Co. (MSD Manuals), 2024–26 (link)

- Competency Based Undergraduate Curriculum, Vol III: Obstetrics & Gynaecology (OG24, OG29) — National Medical Commission, 2024

## Test Yourself: Practice Questions

Thirty questions in NEET PG style, most of them clinical vignettes.

## Practice Questions (NEET PG pattern)

*Original questions written in the style of the exam: +4 for a correct answer, −1 for a wrong one. Every answer
was checked against the sources listed above. NEET PG papers are not published by NBEMS, so these are not past-paper questions.*

**Q1.** A normal menstrual cycle (MSD) has a frequency of

- (a) 24–38 days

- (b) 14–21 days

- (c) 35–45 days

- (d) 21–28 days only

**Answer: (a)** — ≤8 days, <80 ml.

**Q2.** Heavy menstrual bleeding is blood loss per period of more than

- (a) 30 ml

- (b) 500 ml

- (c) 80 ml

- (d) 200 ml

**Answer: (c)** — MSD.

**Q3.** In PALM-COEIN, the structural causes are

- (a) coagulopathy and ovulatory dysfunction

- (b) iatrogenic only

- (c) polyp, adenomyosis, leiomyoma, malignancy/hyperplasia

- (d) endometrial and not classified

**Answer: (c)** — COEIN non-structural.

**Q4.** The commonest cause of AUB is

- (a) fibroids

- (b) ovulatory dysfunction

- (c) coagulopathy

- (d) endometrial cancer

**Answer: (b)** — Teens and >45.

**Q5.** A 15-year-old has heavy, irregular bleeding since menarche. First test per MSD and ICMR includes

- (a) hysteroscopy

- (b) MRI pelvis

- (c) pregnancy test

- (d) endometrial biopsy

**Answer: (c)** — Exclude pregnancy even in adolescents.

**Q6.** A teenager with heavy periods has abnormal initial coagulation tests. MSD advises further testing for

- (a) PCOS only

- (b) endometrial cancer

- (c) von Willebrand disease

- (d) Turner syndrome

**Answer: (c)** — Coagulopathy.

**Q7.** Regular cycles with heavy prolonged bleeding most suggest

- (a) a structural cause

- (b) pregnancy

- (c) anovulation

- (d) menopause

**Answer: (a)** — Irregular = ovulatory.

**Q8.** A 44-year-old with heavy bleeding has endometrial thickness of 15 mm. Per ICMR, next:

- (a) hysterectomy

- (b) start OCPs only

- (c) reassure

- (d) endometrial sampling for histopathology

**Answer: (d)** — ET >12 mm.

**Q9.** Per ICMR, a high risk for endometrial cancer in HMB includes

- (a) high parity

- (b) smoking only

- (c) obesity, diabetes, PCOD, low parity

- (d) IUCD use

**Answer: (c)** — Sample.

**Q10.** Among progestogens, the best haemostasis in HMB (ICMR) is with

- (a) desogestrel

- (b) dydrogesterone

- (c) micronised progesterone

- (d) norethisterone

**Answer: (d)** — Max 40 mg/day.

**Q11.** Cyclical progestogen regimen for HMB per ICMR is given for

- (a) 3 weeks from day 5, repeated for 4–6 cycles

- (b) continuously for 2 years

- (c) 5 days only

- (d) 1 day per month

**Answer: (a)** — Norethisterone or MPA.

**Q12.** A woman bleeding heavily with Hb 6.5 g/dL arrives at the tertiary centre. ICMR acute management:

- (a) oral iron only

- (b) IV tranexamic acid 1 g and blood transfusion

- (c) OCPs and discharge

- (d) immediate hysterectomy

**Answer: (b)** — Then oral TXA 5 days.

**Q13.** After IV tranexamic acid, oral tranexamic acid per ICMR is

- (a) 100 mg daily for 3 months

- (b) not needed

- (c) 5 g once

- (d) 0.5–1 g every 6–8 hours for 5 days

**Answer: (d)** — Acute episode.

**Q14.** Endometrial hyperplasia without atypia is first treated with

- (a) observation only

- (b) oestrogen therapy

- (c) LNG-IUS or progestogens for 6 months

- (d) immediate hysterectomy

**Answer: (c)** — ICMR.

**Q15.** Endometrial hyperplasia with atypia in a woman who has completed her family is an indication for

- (a) hysterectomy

- (b) OCPs

- (c) tranexamic acid only

- (d) observation

**Answer: (a)** — ICMR hysterectomy STW.

**Q16.** Approximately what proportion of women will have fibroids in their lifetime (ICMR)?

- (a) 5%

- (b) 20%

- (c) 80%

- (d) 100%

**Answer: (c)** — Commonest benign uterine tumour.

**Q17.** A FIGO type 0 fibroid is

- (a) cervical

- (b) subserosal pedunculated

- (c) pedunculated and intracavitary

- (d) entirely intramural

**Answer: (c)** — Submucous.

**Q18.** A FIGO type 7 fibroid is

- (a) subserosal pedunculated

- (b) intracavitary

- (c) >50% intramural submucous

- (d) cervical

**Answer: (a)** — 5–7 subserous.

**Q19.** A 38-year-old has a 3 cm asymptomatic intramural fibroid found on scan. ICMR advice:

- (a) hysterectomy

- (b) no treatment needed

- (c) GnRH agonist for a year

- (d) myomectomy

**Answer: (b)** — <5 cm asymptomatic.

**Q20.** Fibroids enlarge in reproductive years and shrink after menopause because they are

- (a) progesterone-deficient

- (b) androgen-dependent

- (c) oestrogen-responsive

- (d) infection-driven

**Answer: (c)** — MSD.

**Q21.** A pregnant woman at 20 weeks with a known fibroid develops acute pain over it. Likely

- (a) torsion of ovary

- (b) sarcomatous change

- (c) red degeneration

- (d) calcific degeneration

**Answer: (c)** — Pregnancy.

**Q22.** Malignant (sarcomatous) change in fibroids occurs in

- (a) about 25%

- (b) about 10%

- (c) half

- (d) less than 1%

**Answer: (d)** — MSD.

**Q23.** A factor associated with lower fibroid risk is

- (a) obesity

- (b) hypertension

- (c) parity of 3 or more

- (d) early menarche

**Answer: (c)** — MSD.

**Q24.** A thin-stalked endometrial polyp causing intermenstrual bleeding is best managed by

- (a) OCPs

- (b) hysteroscopic removal

- (c) hysterectomy

- (d) observation forever

**Answer: (b)** — ICMR.

**Q25.** A 28-year-old nulliparous woman with a symptomatic 7 cm fibroid wants children. Preferred surgery:

- (a) endometrial ablation

- (b) hysterectomy

- (c) bilateral oophorectomy

- (d) myomectomy

**Answer: (d)** — Young/low parity.

**Q26.** A 42-year-old with heavy painful periods has a diffusely enlarged, globular uterus of about 10 weeks' size. Most likely

- (a) adenomyosis

- (b) pedunculated subserous fibroid

- (c) pregnancy

- (d) ovarian cyst

**Answer: (a)** — Rarely >12 weeks.

**Q27.** Before a hysterectomy for a benign condition in a 34-year-old, ICMR mandates

- (a) a second opinion from a qualified gynaecologist

- (b) a court order

- (c) a CT scan

- (d) husband's consent

**Answer: (a)** — <40 or low parity.

**Q28.** Per ICMR, hysterectomy is indicated for an asymptomatic fibroid uterus of size

- (a) any size

- (b) never

- (c) 8 weeks

- (d) 14 weeks or more

**Answer: (d)** — Or hydroureteronephrosis.

**Q29.** ICMR lists which as NOT an indication for hysterectomy?

- (a) fibroid causing hydroureteronephrosis

- (b) CIN III

- (c) atypical endometrial hyperplasia

- (d) white discharge or cervicitis

**Answer: (d)** — Also minor prolapse.

**Q30.** During hysterectomy for a benign condition in a premenopausal woman, ICMR recommends

- (a) removing the ovaries only

- (b) removing both ovaries routinely

- (c) preserving the ovaries and removing both tubes

- (d) leaving the tubes

**Answer: (c)** — Reduces ovarian cancer.

### Active Recall

From memory: give normal menstrual limits and PALM-COEIN, outline the ICMR work-up and medical treatment of heavy menstrual bleeding including the acute episode, describe when to sample the endometrium and how to treat hyperplasia, classify and manage fibroids and polyps, and list ICMR indications and non-indications for hysterectomy.
